RxDoctor Payments DataLook up a doctor →

Jenna Pawloski

Family · Utica, NYNPI 1659866754

Payments from drug & device makers

$62,049in general payments, 2019–2025

Across 977 payments — averaging $63.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$38K
  • Sun Pharmaceutical Industries Inc.$6K
  • AbbVie$5K
  • Johnson & Johnson$4K
  • UCB, Inc.$1K
  • Incyte Corporation$1K
  • plus $7K from 20 others

What the payments were for

  • Consulting fees$4,8038%
  • Speaking & faculty fees$39,33763%
  • Travel & lodging$2,0133%
  • Food & beverage$15,04124%
  • Education$8551%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,049 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$162,334
Medicare patients
474
Services billed
6,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab55$210,617
OtezlaApremilast21$162,554
Clobetasol Propionate156$7,459
Betamethasone Dipropionate75$3,391
Fluorouracil44$3,335
Tacrolimus29$2,479
Metronidazole28$2,119
Imiquimod56$1,542
Clindamycin Phosphate37$1,442
Triamcinolone Acetonide175$1,295
Ketoconazole70$1,177
Econazole Nitrate21$946
Doxycycline Hyclate30$412
Minocycline Hcl21$322
Minoxidil56$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$37,999$162,55421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →